Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution

Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution - Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035705

Enrollment

Registered

2019-01-28

Start date

2019-01-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dialysis patients treated by OL-HDF. The patient selection criteria required patients to be 20 years or older, but did not concern gender, inpatient/outpatient classification, medical history, or the presence of complications for the patient. We excluded patients with significant inflammatory symptoms and severe impairment of the liver, heart, lungs, etc.

Interventions

TDF20-PV (TDF: Toray Medical Co., Ltd.) The usage period is 4 weeks. GDF-21 (GDF: Nikkiso Co., Ltd.) The usage period is 4 weeks. MFX-25U eco (MFX: NIPRO) The usage period is 4 weeks. FIX-250S ec

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient selection criteria required patients to be 20 years or older, but did not concern gender, inpatient/outpatient classification, medical history, or the presence of complications for the patient.

Exclusion criteria

Exclusion criteria: We excluded patients with significant inflammatory symptoms and severe impairment of the liver, heart, lungs, etc.

Design outcomes

Primary

Measure	Time frame
The evaluation items were the removal rate (RR) of B2- microglobulin (B2-MG) and the RR of A1-microglobulin (A1-MG), the removed B2-MG quantity and A1-MG, the albumin leakage quantity, the selective removal index of A1-MG (SRIA), and TMP for each treatment group. The SRIA was calculated as the removed A1-MG quantity divided by the albumin leakage quantity in a single session. We also evaluated the relationship between the removed A1-MG quantity and the albumin leakage quantity	—

Measure

Time frame

The evaluation items were the removal rate (RR) of B2- microglobulin (B2-MG) and the RR of A1-microglobulin (A1-MG), the removed B2-MG quantity and A1-MG, the albumin leakage quantity, the selective removal index of A1-MG (SRIA), and TMP for each treatment group. The SRIA was calculated as the removed A1-MG quantity divided by the albumin leakage quantity in a single session. We also evaluated the relationship between the removed A1-MG quantity and the albumin leakage quantity

—

Countries

Japan

Contacts

Public ContactYusaku Tanaka

Kawashima Hospital Clinical Engineering Department

yu-tanaka0724@khg.or.jp088-631-0110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026